FrançaisWhat if you had invested in Sarepta Therapeutics (SRPT)?
📈 See the interactive version (live chart) →
Calculator: how much would I have made?
If you had invested $1000…
| Investment | Value today | Gain |
|---|---|---|
| 1 years ago (2025) | $148 | -85% |
| 3 years ago (2023) | $139 | -86% |
| 5 years ago (2021) | $105 | -89% |
| 10 years ago (2016) | $466 | -53% |
| since 1997 | $448 | -55% |
Performance and « what if you had invested » — year by year
| Year | Year's return | $1,000 invested at year start → worth today |
|---|---|---|
| 2026 (YTD) | -17% | $835 (-17%) |
| 2025 | -82% | $148 (-85%) |
| 2024 | +26% | $186 (-81%) |
| 2023 | -26% | $139 (-86%) |
| 2022 | +44% | $199 (-80%) |
| 2021 | -47% | $105 (-89%) |
| 2020 | +32% | $139 (-86%) |
| 2019 | +18% | $165 (-84%) |
| 2018 | +96% | $323 (-68%) |
| 2017 | +103% | $655 (-35%) |
| 2016 | -29% | $466 (-53%) |
📊 See the analyst analysis of Sarepta Therapeutics →
Frequently asked questions
How much would I have made investing in Sarepta Therapeutics?
$1000 invested in Sarepta Therapeutics 5 years ago would be worth $105 today, and $466 over 10 years (price return, excluding dividends).
What was Sarepta Therapeutics's return in recent years?
Calendar-year returns — 2024: +26%. 2025: -82%. 2026: -17%. Full breakdown in the table above.
What is Sarepta Therapeutics's average annual return?
Over 10 years, Sarepta Therapeutics's average annual return (CAGR) is about -7% per year, and -36%/yr over 5 years.
What was Sarepta Therapeutics's best and worst year?
Best year: 2017 (+103%). Worst year: 2025 (-82%).
What if I had invested a different amount ($100, $5,000, $10,000) in Sarepta Therapeutics?
It's proportional — just multiply. Over 5 years, $1,000 invested in Sarepta Therapeutics is worth $105, so $100 would be worth a tenth, $5,000 five times more, and $10,000 ten times more. Use the calculator at the top of the page for your exact amount and chosen year.
What is JPI Invest?
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best — on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
- 🏆 Analyst leaderboard by real reliability (beating their sector, not just riding the rally)
- 🎯 What to buy: 3 backtested methods over 6 years, from cautious to aggressive
- 💬 AI assistant: ask anything about any stock, with the numbers
- 📊 Portfolio tracking + 🔔 price alerts by email
⚠️ Past performance, no predictive value and not investment advice. Prices in $, excluding dividends. Data: Yahoo Finance.